A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Part of paid clinical trials in Webster, Texas.
- Sponsor
- Cullinan Therapeutics Inc.
- Study ID
- NCT07738822
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Immune Thrombocytopenia (ITP)
- Warm Autoimmune Hemolytic Anemia (WAIHA)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Velinotamig specified dose on specified days. — DRUGVelinotamig is an engineered bispecific antibody directed against BCMA and CD3.
Study Details
A Phase 1b/2a, open-label dose escalation and dose expansion study of subcutaneously (SC) administered velinotamig for the treatment of adults with relapsing and refractory immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to evaluate safety and tolerability.
Key Dates
- First listed
- Jul 31, 2026
- Start date
- Dec 31, 2026
- Status verified
- Jul 2026
- Primary completion
- Jan 31, 2029
- Completion
- Jan 31, 2031
Study Design
- Enrollment
- 72 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Part A: Dose Escalation.Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose escalation cohorts.
- Experimental: Part B: Dose Expansion.Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose expansion cohorts.
Primary Outcome Measure
Safety and Tolerability [ Time Frame: 48 weeks ]
Central Contacts
- Shane McLoughlin+16178609878
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cullinan Investigative Site | Webster | Texas | 77598 |
Find similar trials in Webster, TX
By research site
Related Studies
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)PHASE1 · Recruiting · Chugai Pharmaceutical · Orange, California
- A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaPHASE1/PHASE2 · Recruiting · Eli Lilly and Company · Los Angeles, California
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune ThrombocytopeniaPHASE2 · Recruiting · Nuvig Therapeutics, Inc. · Greenville, North Carolina
- Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseasePHASE1/PHASE2 · Recruiting · CRISPR Therapeutics AG · Rochester, Minnesota